News / Events

Featured News Stories

  • January 27, 2010

    ENDO AND JUBILANT EXPAND ONCOLOGY DISCOVERY PARTNERSHIP ON SUCCESSFUL DELIVERY OF EARLY MILESTONE

    Download PDF | View Short Summary

    Bangalore, India, January 27, 2010 -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals (Nasdaq: ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

    The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

  • January 11, 2010

    DISCOVERX CORP. & JUBILANT BIOSYS ANNOUNCE CO-MARKETING AGREEMENT FOR SCREENING SERVICES

    Download PDF | View Short Summary

    Jubilant Biosys Limited, based in Bangalore, an integrated Drug Discovery and Development solution provider, a subsidiary of Jubilant Organosys Ltd, headquartered in Noida, announced today that it has entered into a co-marketing agreement to provide screening solutions, with DiscoveRx Corporation (Fermont, USA), a premier provider of innovative cell based assay solutions for GPCR, Kinases, NHR and Proteases.

    This agreement allows Jubilant access to DiscoveRx PathHunterTM and cAMPHunterTM cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant's customers. The agreement also enables DiscoveRx to expand its platform technology to offer screening solutions from India.

  • December 15, 2009

    HARI S. BHARTIA, CO-CHAIRMAN AND MANAGING DIRECTOR OF JUBILANT ORGANOSYS, AWARDED PERSON OF THE YEAR AT 2009 BIOSPECTRUM AWARDS

    Download PDF

  • December 1, 2009

    JUBILANT AND LILLY EXTEND DRUG DISCOVERY COLLABORATION ON SUCCESSFUL DELIVERY OF PRE-CLINICAL CANDIDATES

    Download PDF | View Short Summary

    NOIDA, (UP) INDIA, December 1, 2009 - Jubilant Organosys Ltd., through its subsidiary Jubilant Biosys Ltd, based in Bangalore announced today that its 4 year old research collaboration with Eli Lilly & Company, has successfully delivered multiple discovery milestones and preclinical candidates, resulting in a five-year extension and an expanded portfolio collaboration.

    Jubilant and Lilly had entered into an initial discovery research collaboration in late 2005. Lilly will continue to own any compounds developed under the collaboration and will be responsible for worldwide commercialization.

    Lilly and Jubilant had also established a joint venture, Vanthys Pharmaceuticals, for early stage drug development in 2008. Under the terms of the new 5 year agreement Jubilant will receive research funding and success-based discovery and development milestones.

  • November 23, 2009

    JUBILANT ORGANOSYS, UAB AND SOUTHERN RESEARCH ENTER INTO DRUG DISCOVERY JOINT VENTURE

    Download PDF | View Short Summary

    BIRMINGHAM, Ala. USA/ Noida (UP) India-Nov. 23, 2009-Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide. A Memorandum of Understanding was signed today in Washington, DC. Key components of the agreement include:

  • November 10, 2009

    DUKE UNIVERSITY AND JUBILANT ORGANOSYS ANNOUNCE INTENT TO ENTER GLOBAL RESEARCH AND DRUG DEVELOPMENT PARTNERSHIP
    Download PDF | View Short Summary

    NEW DELHI, INDIA (November 10, 2009) - Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies. The proposed partnership will also advance both organizations' mutual commitment to reducing global health disparities. The Parties shall complete definitive agreements by the first quarter of 2010.

    Under the terms of this proposed partnership, Duke and Jubilant will work towards jointly selecting and managing a portfolio of translational research projects that leverages expertise and thought leadership from Duke University scientists and development capabilities including funding from Jubilant. The parties shall commit to work together over a period of five years with the objective of developing a portfolio of 4-5 technologies at steady state over the period of collaboration.

  • October 2, 2009

    KAREN LEWIS JOINS CLINSYS AS VICE PRESIDENT OF GLOBAL CLINICAL OPERATIONS
    Download PDF | View Short Summary

    BEDMINSTER, NEW JERSEY (October 2, 2009) - Clinsys Clinical Research, Inc.®, a therapeutically focused clinical research organization, today announced that Karen Lewis has joined the company as Vice President of Global Clinical Operations. Ms. Lewis brings more than 20 years of clinical research experience in multiple therapeutic areas including infectious disease, gastrointestinal diseases, cardiovascular, central nervous system, ophthalmology, dermatology and women's health.

    In her role at Clinsys, Ms. Lewis will be responsible for the project management and field operations groups including training, development and growth initiatives. She will also work to develop the strategic direction, global integration and expansion of clinical operations for the company.

    "Clinsys is a premier leader in the CRO industry, and I am honored to have the opportunity to join the talented individuals within this organization as Clinsys continues to provide quality service to its clients," stated Ms. Lewis.

  • June 11, 2009

    JUBLIANT TO WORK WITH ENDO PHARMACEUTICALS ON DRUG DEVELOPMENT
    Collaboration to provide Endo Pharmaceuticals with new drug candidates in Oncology
    Download PDF | View Short Summary

    NOIDA, INDIA (June 11, 2009) - Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of Oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.

  • June 10, 2009

    TRIALSTAT FEATURED IN THE OTTAWA BUSINESS JOURNAL
    View Article

  • May 5, 2009

    JUBILANT ENTERS RESEARCH COLLABORATION WITH ASTRAZENECA
    Research collaboration to provide AstraZeneca with new preclinical drug candidates
    Download PDF | View Short Summary

    NOIDA, INDIA (May 5, 2009) - Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research collaboration agreement with, AstraZeneca, and focused on delivering novel drug candidates into the international pharmaceutical company's pre-clinical pipeline. Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca.

    AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant will be eligible to receive research funding spanning an initial five-year period. In addition, AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialization of any of the compounds.

  • March 18, 2009

    CLINSYS PARTNERS WITH NC STATE UNIVERSITY FOR SIX SIGMA GREEN BELT TRAINING
    Download PDF | View Short Summary

    BEDMINSTER, NEW JERSEY (March 18, 2009) - Clinsys Clinical Research, Inc.®, a therapeutically focused global contract research organization, announced its partnership with North Carolina State University (NCSU) to provide 20 Clinsys employees with Six Sigma Green Belt training. During the month of March, these employees will participate in a two-part training program directed by NCSU's College of Textiles and Industrial Extension Service (IES) departments.

  • March 16, 2009

    CLINSYS CEO DAVID WILLIAMS NAMED 2009 TOP BUSINESS LEADER
    View Article

  • January 29, 2009

    KIMMEL APPOINTED AS ACADEMY CHAIR OF ACRP
    Download PDF | View Short Summary

    BEDMINSTER, NEW JERSEY (January 29, 2009) - Clinsys Clinical Research, Inc.®, a therapeutically focused global contract research organization, announced the appointment of Kathryn Kimmel, CCRC, CCRA, a Senior Clinical Research Associate (CRA), as chair of the Academy Board of Trustees for the Association of Clinical Research Professionals (ACRP). The Academy oversees ACRP certification functions related to members who are CRAs, clinical research coordinators (CRCs) and nonphysician clinical trial investigators (CTIs).

  • January 26, 2009

    CLINSYS ECSTATIC OVER TRIALSTAT CA EDC ACQUISITION
    View Article

  • December 8, 2008

    CLINSYS ENTERS EDC NICHE
    View Article

  • November 18, 2008

    CLINPAGE DISCUSSES STRATEGY BEHIND CLINSYS' ACQUISITION OF TRIALSTAT CLINICALANALYTICS
    View Article

  • November 17, 2008

    JUBILANT AUGMENTS CLINSYS CLINICAL RESEARCH® THROUGH ACQUISITION OF TRIALSTAT CLINICALANALYTICS®, AN EDC PLATFORM
    Download PDF | View Short Summary

    NOIDA, INDIA (November 17, 2008) - Jubilant Organosys Ltd. announced today that its subsidiary Clinsys Clinical Research, Inc.®, New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics® from TrialStat® for a purchase consideration of CAD 750,000.

    TrialStat ClinicalAnalytics (TrialStat CA) is a Web-based electronic data capture (EDC) solution currently used by a wide range of pharmaceutical and CRO customers worldwide. TrialStat CA is the industry's first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively.

    Clinsys extensive global resources will enable TrialStat to continue its proven record of growth, customer service and product innovation. This agreement will give TrialStat's existing CRO and biopharmaceutical customer base a broader scope of services.

    "The Company had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally" said David E. Williams, Chief Executive Officer of Clinsys.